Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 97

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 97
---
00 per share, the initial public offering price of the units) after the initial business combination even if public investors experience substantial losses and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. In addition, our sponsor has committed to purchase an aggregate of 400,000 private units (or 430,000 private units if the underwriters’ option to purchase additional units is exercised in full) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters’ option to purchase additional units is exercised in full), that will also be worthless if we do not complete a business combination. Each private unit will consist of one ordinary share and one right to receive one -eighth(1/8) of an ordinary share upon the consummation of an initial business combination. The private units are identical to the units sold in this offering, subject to certain limited exceptions as described in this prospectus. The non -managingsponsor investors have indicated an interest to indirectly purchase, through the purchase of non -managingsponsor membership interests, an aggregate of 50,000 of the 400,000 private placement units (or 430,000 private placement units if the underwriters’ over -allotmentoption is exercised in full) being purchased by our sponsor at a price of $10.00 per unit ($500,000 in the aggregate) in a private placement that will close simultaneously with the closing of this offering. Subject to each non -managingsponsor investor purchasing, through the sponsor, the private placement units allocated to it in connection with the closing of this offering, the sponsor will issue membership interests at a nominal purchase price to the non -managingsponsor investors reflecting interests in an aggregate of 666,667 founder shares held by the sponsor. The non -managingsponsor investors will not be subject to transfer restrictions or a lock -upagreement on any public shares that they may purchase in this offering pursuant to the expressions of interest described below or otherwise. The founder shares are identical to the ordinary shares included in the units being sold in this offering except that: (1) the founder shares are subject to certain transfer restrictions contained in a letter agreement that our initial shareholders, directors and officers have entered into with us; (2) pursuant to such letter agreement, our initial shareholders, directors and officers have agreed to waive